-

Avilar Therapeutics to Present New Data for ATAC Extracellular Protein Degraders at Targeted Protein Degradation Summit

WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present new preclinical data from its ATAC (ASGPR Targeting Chimera) degrader platform at the sixth annual Targeted Protein Degradation Summit being held in Boston on October 30 – November 2, 2023.

ATACs are bifunctional molecules comprising one of Avilar’s novel ligands to the asialoglycoprotein receptor (ASGPR) conjugated to another ligand that binds to a disease-causing extracellular protein. ATACs work by shuttling pathogenic proteins from circulation into the endolysosome where the unwanted proteins are degraded.

The presentation will showcase new ATAC mechanism of action studies that confirm Avilar’s ASGPR ligands retain key pH- and calcium-dependent binding properties similar to and consistent with the known behavior of well-characterized ASGPR ligands such as GalNAc. These properties enable normal ASGPR release and recycling after ATAC internalization within the early endosome, and further elucidate the ATAC mechanism to harness the natural ASGPR pathway for degradation of extracellular protein targets.

New in vivo data will also be presented that robustly characterize the relationship between ATAC pharmacokinetics, binding properties of the ATAC ligands to ASGPR and target protein IgG, and ASGPR-mediated degradation.

Details of the presentation are as follows:

Title: Heterobifunctional Molecules That Induce Targeted Degradation of Extracellular Proteins Through the Cell-Surface Asialoglycoprotein Receptor
Session: Expanding the Scope of TPD by Leveraging the Ability to Degrade Extracellularly
Presenter: Jason Wiles, PhD, Vice President, Discovery and Preclinical Sciences
Date and Time: Thursday, November 2, 11 a.m. ET

The slides will be available on the Avilar website following the presentation.

About Avilar Therapeutics
Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary discovery platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC mediated endocytosis and degradation. This platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging its ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar is based in Waltham, MA. For more information, please visit www.avilar-tx.com and follow us on LinkedIn.

Contacts

Media:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Avilar Therapeutics


Release Versions

Contacts

Media:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Social Media Profiles
More News From Avilar Therapeutics

Avilar Therapeutics to Present Preclinical Data for MTAC (M6PR Targeting Chimera) Extracellular Protein Degrader Platform at the American Association of Immunologists Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical proof-of-concept data for the company’s MTAC (M6PR Targeting Chimera) protein degrader platform at IMMUNOLOGY™ 2024, the American Association of Immunologists annual meeting taking place May 3-7 in Chicago, Illinois. MTACs are novel bifunctional molecules containing a proprietary Avilar ligand to the mannose 6‑phosphate recep...

Avilar Therapeutics Receives U.S. Patent for Novel Extracellular Protein Degraders

WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that the U.S. Patent and Trademark Office issued U.S. Patent 11,819,551 on November 21, 2023. The issued patent provides broad protection for Avilar’s first wave of extracellular proteins degraders called ATACs (ASGPR Targeting Chimeras) with therapeutic applications in a wide range of human diseases. ATACs are bi-functional molecules that leverage Avil...

Avilar Therapeutics to Present at Upcoming Industry Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that its company leaders will participate in two upcoming industry conferences, highlighting the company’s proprietary protein degradation platform capabilities and associated opportunities to target historically intractable pathogenic proteins. Avilar will present on the degradation of extracellular proteins using ASGPR targeting chimeras (ATACs) at Pr...
Back to Newsroom